EUNETWORKS-FIBER-UK-LTD.
21.9.2022 10:01:49 CEST | Business Wire | Press release
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, has deployed a new ultra low latency route between Basildon and London in the UK that connects the ICE data centre to Interxion LON1 & 2: A Digital Realty Company, and onwards to Slough. These are critical locations for financial markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005083/en/
Paula Cogan, President euNetworks (Photo: Business Wire)
The new route is over 45km long and includes 14km of ultra low latency CoreSmart® cable. Lumenisity® Limited (“Lumenisity”) supplied the award-winning CoreSmart cable, which is based on NANF® hollowcore technology to enable transmission over long distances and is compatible with regular single mode fibre – both major constraints on other hollowcore fibre architectures. The route is the longest commercial deployment of hollowcore fibre technology to date and its use is exclusive to euNetworks and its customers. It is also the first commercial construction of a long distance hybrid route of hollowcore fibre and regular single mode fibre.
Offering euNetworks’ dedicated network platform euTrade, at bandwidths between 1G and 10G, this hybrid route is 10% faster than an equivalent all single mode fibre cable. It’s the third deployment for euNetworks following successful deliveries of the first hollowcore fibre based commercial route in April 2021 and the second in March earlier this year.
“We have successfully delivered increasingly longer deployments of hollowcore fibre in our network, becoming the first fibre provider in the world to utilise the benefits of this new fibre technology in commercial markets,” said Paula Cogan, President of euNetworks. “From the initial 1km pilot, the teams have gone on to deploy hollowcore cable lengths of 7km and 14km on our network, as well as successfully blending hollowcore fibre with regular single mode fibre on this latest route. We continue to be focused on delivering the best possible bandwidth solutions for our customers and look forward to deploying longer routes with Lumenisity in the coming quarters. Leading the market in fibre-based ultra low latency services throughout Europe remains a key focus for euNetworks.”
“We are pleased to partner with euNetworks again, successfully deploying this new route and achieving this hollowcore cable link length”, said Tony Pearson, VP Sales & Marketing at Lumenisity. “We are excited to reach this milestone with euNetworks, and will continue to deliver a unique cable solution offering longer reach and lower latency for their customers.”
Data travels 50% faster in hollowcore cable, reducing latency by 33%, and providing a round trip saving of 3μs (three microseconds) per kilometre. These latency savings are hugely significant in financial trading applications. They can also be scaled to increase the separation of data centres by 50%, whilst maintaining the latency envelope, more than doubling the area of land in which these data centres can be located.
euNetworks’ euTrade solution is a dedicated network platform supporting the bandwidth needs of the financial services community. The company continues to optimise routes between all the key trading exchanges in Europe, and is supporting major exchange moves this year. This focus ensures delivery of the shortest paths and lowest latencies available in the market.
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 480 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Lumenisity® Limited
Lumenisity is an established independent company originally spun out from the world-renowned Optoelectronics Research Centre (ORC) at the University of Southampton. Formed in 2017 to commercialise breakthroughs in the development of hollowcore optical fibre at the ORC, the company has built a team of industry leaders and experts to realise their goal to be the world’s premier high-performance hollowcore fibre optic cable solutions provider offering their customers reliable, deployable, low latency and high bandwidth connections that unlock new capabilities in communication networks. Lumenisity®, NANF® and Coresmart® are registered trademarks of Lumenisity Limited.
Visit our website at: www.lumenisity.com and visit the team on booth 369 at the ECOC 2022 Exhibition in Basel (19th – 21st September) to find out more about our hollowcore cable solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom